<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-112548</identifier>
<setSpec>0034-9356</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The 2013 Seville Consensus Document on alternatives to allogenic blood transfusion. An update on the Seville Document</dc:title>
<dc:description xml:lang="en">Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of factors, including the specialty of the physician, knowledge and preferences, the degree of anemia, transfusion policy, and AABT availability. Since AABTs are not harmless and may not meet cost-effectiveness criteria, such variability is unacceptable. The Spanish Societies of Anesthesiology (SEDAR), Hematology and Hemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Hemostasis (SETH) and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these 6 Societies have conducted a systematic review of the medical literature and have developed the 2013 Seville Consensus Document on Alternatives to Allogeneic Blood Transfusion, which only considers those AABT aimed at decreasing the transfusion of packed red cells. AABTs are defined as any pharmacological or non-pharmacological measure aimed at decreasing the transfusion of red blood cell concentrates, while preserving patient safety. For each AABT, the main question formulated, positively or negatively, is: &#147;Does this particular AABT reduce the transfusion rate or not?&#148; All the recommendations on the use of AABTs were formulated according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) methodology(AU)</dc:description>
<dc:creator>Muñoz, M</dc:creator>
<dc:creator>López-Briz, E</dc:creator>
<dc:creator>Torrabadella, P</dc:creator>
<dc:creator>Fernández-Mondéjar, E</dc:creator>
<dc:creator>Fernández, J. A</dc:creator>
<dc:creator>Asuero, M</dc:creator>
<dc:creator>Bóveda, J. L</dc:creator>
<dc:creator>Sánchez, C</dc:creator>
<dc:creator>Páramo, J. A</dc:creator>
<dc:creator>Bisbe, E</dc:creator>
<dc:creator>Montoro-Ronsano, B</dc:creator>
<dc:creator>Fernández-Hinojosa, E</dc:creator>
<dc:creator>Llau, J. V</dc:creator>
<dc:creator>Ferrándiz, C</dc:creator>
<dc:creator>Leal-Noval, S. R</dc:creator>
<dc:creator>Ruiz, J. C</dc:creator>
<dc:creator>Izuel, M</dc:creator>
<dc:creator>Arellano, V</dc:creator>
<dc:creator>Contreras, E</dc:creator>
<dc:creator>Castillo-Muñoz, A</dc:creator>
<dc:creator>Gómez-Luque, A</dc:creator>
<dc:creator>Jiménez-Yuste, V</dc:creator>
<dc:creator>García-Erce, J. A</dc:creator>
<dc:creator>Quintana, M</dc:creator>
<dc:creator>Candela, A</dc:creator>
<dc:creator>Gomar, C</dc:creator>
<dc:creator>Romero-Garrido, J. A</dc:creator>
<dc:creator>Basora, M</dc:creator>
<dc:creator>Puppo, A</dc:creator>
<dc:creator>García de Lorenzo, A</dc:creator>
<dc:creator>Bautista-Paloma, F. J</dc:creator>
<dc:creator>Fernández, C</dc:creator>
<dc:creator>Moral, V</dc:creator>
<dc:creator>López-Fernández, M. L</dc:creator>
<dc:creator>Colomina, M. J</dc:creator>
<dc:creator>Paniagua, C</dc:creator>
<dc:creator>Salinas-Argente, R</dc:creator>
<dc:creator>Martín-Conde, J. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La transfusión de sangre alogénica (TSA) no es inocua, y como consecuencia han surgido múltiples alternativas a la misma (ATSA). Existe variabilidad respecto a las indicaciones y buen uso de las ATSA. Dependiendo de la especialidad de los médicos que tratan a los pacientes, el grado de anemia, la política transfusional, la disponibilidad de las ATSA y el criterio personal, estas se usan de forma variable. Puesto que las ATSA tampoco son inocuas y pueden no cumplir criterios de coste-efectividad, la variabilidad en su uso es inaceptable. Las sociedades españolas de Anestesiología y Reanimación (SEDAR), Hematología y Hemoterapia (SEHH), Farmacia Hospitalaria (SEFH), Medicina Intensiva y Unidades Coronarias (SEMICYUC), Trombosis y Hemostasia (SETH) y Transfusiones Sanguíneas (SETS) han elaborado un documento de consenso para el buen uso de la ATSA. Un panel de expertos de las 6 sociedades ha llevado a cabo una revisión sistemática de la literatura médica y elaborado el 2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Solo se contempla las ATSA dirigidas a disminuir la transfusión de concentrado de hematíes. Se definen las ATSA como toda medida farmacológica y no farmacológica encaminada a disminuir la transfusión de concentrado de hematíes, preservando siempre la seguridad del paciente. La cuestión principal que se plantea en cada ítem se formula, en forma positiva o negativa, como: «La ATSA en cuestión reduce/no reduce la tasa transfusional». Para formular el grado de recomendación se ha usado la metodología Grades of Recommendation Assessment, Development and Evaluation (GRADE)(AU)</dc:description>
<dc:source>Rev Esp Anestesiol Reanim;60(5): 263e1-263e25, mayo 2013.</dc:source>
<dc:identifier>ibc-112548</dc:identifier>
<dc:title xml:lang="es">2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla</dc:title>
<dc:subject>^d787^s22048</dc:subject>
<dc:subject>^d31478^s22066</dc:subject>
<dc:subject>^d787^s22045</dc:subject>
<dc:subject>^d14575^s22066</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d14575^s22045</dc:subject>
<dc:subject>^d14575^s22048</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d14575^s22039</dc:subject>
<dc:subject>^d31478^s22074</dc:subject>
<dc:subject>^d30313^s22048</dc:subject>
<dc:subject>^d14575^s22074</dc:subject>
<dc:subject>^d30313^s22049</dc:subject>
<dc:subject>^d50303</dc:subject>
<dc:subject>^d50302</dc:subject>
<dc:subject>^d30313^s22074</dc:subject>
<dc:subject>^d787^s22049</dc:subject>
<dc:type>article</dc:type>
<dc:date>201305</dc:date>
</metadata>
</record>
</ibecs-document>
